Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein
Catalog No: NYESO1-HP001
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &SLLMWITQC).
Product Details
- Molecular Aliases
- MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody at 5μg/ml (100μl/well) on the plate. Dose response curve for Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His Tag with the EC50 of 7.2ng/ml determined by ELISA.
Background
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
References
- (1)Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.